FDA Grants Fast Track Designation to IVS-3001 for Renal Cell Carcinoma

The FDA has granted fast track designation IVS-3001 for use as a potential therapeutic option in patients with renal cell carcinoma.

Related Keywords

Texas ,United States ,Samer Srour ,Jake Kushner ,Maung Naing ,Invectys Inc ,University Of Texas Md Anderson Cancer Center ,Cancer Center ,Investigational Cancer Therapeutics ,Stem Cell Transplantation ,Cellular Therapy ,Ivs 3001 ,Patients With Renal Cell Carcinoma ,Nct05672459 ,The University Of Texas Md Anderson Cancer Center ,D ,Invectys ,Nc ,